ESMO Open· @ESMO_Open · X·· 2 天前评分70
正文 · 原文
Addition of Tucatinib to Trastuzumab/Pertuzumab After Local Therapy for Isolated icPD in HER2+mBC: Primary Results of the Ph2 BRIDGET Trial in @ESMO_Open presented at #ESMO2026. Median icPFS not reached (mFUP 19.6 months), 46/47 pts alive @ data cut-off. https://www.esmoopen.com/article/S2059-7029(26)02587-1/fulltext
19 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1766RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Health-related quality of life from HER2CLIMB-05: A phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as 1L maintenance therapy for HER2+ mBC
https://esmocongress.esmo.org来源：ESMO Open · x.com